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Background: We made a comparative study on the antiemetic effect of midazolam and ondansetron added to 
intravenous patient-controlled analgesia (PCA) using fentanyl with gynecologic patients undergoing pelviscopic 
surgery.
Methods: The PCA using 20 μg/kg of fentanyl was started in all groups postoperatively. A dose of 16 mg of 
ondansetron was added to the PCA of group O (n = 30). A dose of 5 mg of midazolam was added to the PCA of group 
M (n = 30). While 16 mg of ondansetron and 5 mg of midazolam were added to the PCA of group MO (n = 30). Total 
volume of the PCA was 60 ml, and the PCA system was programmed to deliver 0.5 ml/h of continuous doses and a 
0.5 ml bolus on demand, with a 15 minutes lockout interval. The incidence of postoperative nausea and vomiting 
(PONV), sedation score, visual analog scale (VAS) for pain, and rescue drug dose for PONV were investigated at the 
postanesthesia care unit (PACU), 6 hours, and 24 hours after recovery.
Results: The incidence of PONV in group MO was significantly lower than in group O at PACU, 24 hours after 
recovery (P < 0.05). The sedation score and VAS pain score showed no differences among all groups.
Conclusions: Midazolam added to PCA using fentanyl proved more effective than ondansetron in preventing PONV 
without adverse effects. (Korean J Anesthesiol 2012; 62: 343-349)
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Introduction
Postoperative nausea and vomiting (PONV) is one of the 
most frequent postoperative complications, and its reported 
incidence rate is 20-30%, despite the use of various antiemetic 
drugs [1]. PONV could reduce patients’ postoperative satisfaction 
and cause severe complications and economic loss, allowed to 
continued.
Various factors could cause continuous PONV. Among them, 
intraoperative or postoperative use of opioids is a factor that 
can be controlled by the anesthesiologist; the frequency and 
intensity of PONV can be reduced by injecting an appropriate 
antiemetic. Intravenous patient-controlled analgesia (IV-
PCA) is used for postoperative pain control, but it may cause 
PONV because of the injected opioids. Ondansetron, a 
5-hydroxytryptamine (5-HT3) receptor antagonist, is widely 
used because it can prevent and treat PONV [2,3] with a 
low incident rate of side effects commmoly caused by other 
antiemetics. However, it has been reported that this type of drug 
does not reduce PONV effectively [4], and that its usefulness is 
low considering to the price [5].
It was recently reported that midazolam, a benzodiazepine 
used for pretreatment to reduce preanesthetic anxiety, reduced 
the frequency and intensity of PONV, showing a sedative 
effect as well as an antiemetic effect [6,7]. Midazolam has 
been used in many different ways to prevent PONV. In a case 
where a mixture of midazolam and morphine was used while 
performing IV-PCA, the treatment was reported as effective and 
helpful in preventing PONV [8].
However, the combined administration of midazolam and 
ondansetron for PONV has not been reported internationally; 
thus, the aim of this study was to investigate the effect of the 
combined administration of midazolam and ondansetron on 
PONV.
Materials and Methods
The subjects of this study were patients classified as 
American Society of Anesthesiologists I and II, they were 
supposed to undergo general anesthesia and postoperative IV-
PCA for a pelviscopic gynecological surgery. They ranged in 
age from between 20 and 60 years old, and their body weight 
was between 50 kg and 70 kg. Patients who had a history of 
smoking, those who had a history of PONV or kinesia, and those 
who were extremely obese with a body mass index (BMI) of 
40 or higher were excluded from the study. Before conducting 
the study, participants were given an explanation about the 
purpose of the study and the side effects that might occur with 
the use of mixed opioids for IV-PCA, and their written consent 
was obtained. The incident rate of PONV was considered as 
the primary outcome measures of this study, and the degree of 
sedation and pain were investigated together. 
As premedication for all the patients in the wards, 0.2 mg of 
glycopyrrolate was intramuscularly injected 30 minutes before 
starting the anesthesia. Anesthesia was induced with 2 μg/kg of 
fentanyl, 5 mg/kg of thiopental, and 0.6 mg/kg of rocuronium. 
Following intubation, inhalation anesthesia was maintained 
with N2O 1.5 L/min, O2 1.5 L/min, and sevoflurane of 2-3 vol%. 
While maintaining anesthesia, the tidal volume was regulated 
to keep the end tidal CO2 pressure in the range of 30-35 mmHg. 
Sevoflurane of 1 vol% was maintained around the time when the 
skin suture began, but the inhalation anesthetic was stopped at 
the end of the surgery. According to the mixed antiemetics, the 
subjects were divided into three groups: O Group, in which 16 mg 
of ondansetron (Ondant Injection 8 mg
Ⓡ, Hanmi Pharm, Seoul, 
Korea) was injected, the M Group, in which 5 mg of midazolam 
(Bukwang Midazolam Injection
Ⓡ, Bukwang Pharm, Seoul, Korea) 
was injected, and the MO Group, in which 16 mg of ondansetron 
and 5 mg of midazolam were mixed and injected. There was 
no difference in the age, weight, and height of the subjects 
among the groups (Table 1). The instrument used for IV-PCA 
was the Basal/Bolus Infusor (Baxter Healthcare Corporation, 
USA). Before starting anesthesia, 20 μg/kg of fentanyl and the 
respective antiemetic were mixed with a final solution volume 
of 60 ml, and infused into the patients. Continuous infusion 
was set at 0.5 ml/h with a bolus of 0.5 ml and a lockout time 
of 15 minutes. Before conducting the study, midazolam and 
ondansetron were mixed in normal saline solution and it was 
verified that no crystal formed for two days by macroscopic 
and microscopic observation. Stewart et al. reported that 
the mixed infusion of ondansetron with midazolam and 
fentanyl was stable for 24 hours [9]. In a study by Chiaretti et 
al. [10], an effective result was achieved without any particular 
problems when fentanyl and midazolam were mixed and 
infused into PCA patients. Thus, the authors considered the 
mixed solution of fentanyl, ondansetron, and midazolam to be 
Table 1. Demographic Data
Group O 
(n = 30)
Group M 
(n = 30)
Group MO 
(n = 30)
Age (yr)
Weight (kg)
Height (cm)
Anesthesia time (min)
PACU stay time (min)
38.5 ± 8.5
57.1 ± 7.8
159.0 ± 4.1
116.3 ± 80.9
35.6 ± 10.3
38.0 ± 10.3
56.1 ± 7.3
160.6 ± 5.4
109.4 ± 59.7
31.1 ± 10.8
39.1 ± 8.7
56.4 ± 7.4
158.5 ± 5.4
121.6 ± 67.9
44.0 ± 28.9
Values are mean ± SD. A 16 mg dose of ondansetron is added to the 
PCA of group O; 5 mg of midazolam is added to the PCA of group 
M; and 16 mg of ondansetron and 5 mg of midazolam are added to 
the PCA of group MO. There are no significant differences among 
the groups. PACU: postanesthesia care unit, PCA:  patient controlled 
analgesia.345 www.ekja.org
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safe and physicochemically stable. About 30 minutes before 
the end of the surgery, a bolus of 8 mg of ondansetron was 
intravenously injected, and 0.4 mg of glycopyrrolate and 20 mg 
of pyridostigmine were mixed and intravenously injected in 
order to reverse the muscular relaxation.
At least one incident of nausea or vomiting was considered 
as an incidence of PONV, and the PONV incidence rate was 
investigated for three periods of time: recovery room, from 
the time of recovery to the first 6 hours after coming out of the 
recovery room, and between 6 and 24 hours after recovery. 
When a patient complained of PONV, 8 mg of ondansetron 
was intravenously injected, and it was then verified whether 
PONV was relieved by observing the patient for five minutes. 
If the patient complained of PONV continuously, 10 mg of 
metoclopramide was intravenously injected. If the patient 
complained of PONV despite that, an intravenous injection of 
5 mg of dexamethasone was given. Sedation was assessed with 
the modified observer’s assessment of alertness/sedation (OAA/
S) score [11] (Table 2). If the OAA/S score was 3 or lower, or if 
the tidal rate was 10 times per minute or lower, or if the oxygen 
saturation was 90% or lower, flumazenil, an antagonist of 
benzodiazepine, was injected. The pain was assessed using the 
visual analog scale (VAS, 0-10). Intravenous injection of 30 mg 
of ketorolac was done when the VAS was 5 or higher or when 
the patient complained of severe pain.
After the end of the surgery, when the patient recovered 
consciousness in the recovery room, the PONV incidence, the 
OAA/S score, and the VAS were measured. The PONV inci-
dence, the OAA/S score, the VAS, and the number of ondan-
setron, metoclopramide, dexamethasone and ketorolac 
injections were recorded by visiting the patients at 6 hours and 
24 hours after the recovery, by interviewing the patients as well 
as their caregivers, and by reviewing the clinical chart. All the 
investigations were done by a rater who was not aware of the 
classification of the groups.
Individual measurements were expressed as the percentage 
of the number of patients (%) and the “mean ± standard 
deviation” , and analyzed with SPSS 18.0. For the continuous 
variables, normality was tested by the Shapiro-Wilk test. If the 
distribution was normal, an ANOVA was done and a Tukey test 
was done to compare among the groups. If the distribution was 
not normal, a Kruskal-Wallis test was done and a Bonferroni 
correction was done to compare among the groups. For the 
discrete variables, a Chi-square test or a Fisher’s exact test was 
done, if necessary. The number of subjects was determined by 
referring to the study by Park and Cho. The PONV incidence 
rate of the O group was 66.7% [12]. Assuming that the PONV 
incidence rate of the O group in this study was equal to that of 
the previous study, the PONV incidence rate of the M Group 
and the MO group was set as 33.35%. The number of samples 
for each group was 27 calculated by on-sided test on the basis 
of a significance level of 5% and a power of test of 80%. The total 
number of subjects was 90, assuming a loss rate of 10% for the 
follow-up observation.
Results
There was no difference in the anesthetic time and the 
delayed time in the recovery room (Table 1). The postoperative 
PONV incidence rate measured in the recovery room was 43.3% 
(13 subjects) in the O group, 16.7% (5 subjects) in the M group, 
and 16.7% (5 subjects) in the MO group, with a significantly 
lower incidence rate in the M and MO groups than in the O 
group (P < 0.05). The PONV incidence rate of the MO group 
was significantly lower than that of the O group, from the time 
of leaving the recovery room to the first 6 hours after leaving the 
recovery room (P < 0.05). However, no significant difference 
was found among the groups from 6 hours after leaving the 
recovery room to 24 hours after. The overall PONV incidence 
rate from the recovery room until 24 hours after leaving the 
recovery room was 63.3% (19 subjects) in the O group, 46.7% 
(14 subjects) in the M group, and 33.3% (10 subjects) in the MO 
group. The overall PONV incidence rate of the MO group was 
significantly lower than that of the O group (P < 0.05) (Fig. 1).
The percentage of the patients who experienced nausea or 
vomiting during the time after leving the recovery room until 24 
hours after recovery and thus, required additional antiemetic 
was the highest in the O Group at 53.3% (16 subjects), followed 
by the MO group at 33.3% (10 subjects) and the M Group at 
26.7 (8 subjects). The percentage of the patients who showed 
continued PONV and thus, to whom antiemetics, ondansetron, 
metoclopramide or dexamethasone, were injected two times or 
more was 37.5% (6 subjects) in the O Group, 12.5% (1 subject) 
in the M Group, and 40% (4 subjects) in the MO group (Table 3).
There was no difference in the OAA/S score over time among 
the groups at the time when the subjects were in the recovery 
room and during the time until 6 hours and 24 hours after the 
leaving recovery room (Table 4). No subjects had an OAA/S 
score of 3 or lower or respiratory failure either in the recovery 
room or in the ward for 24 hours after leaving the recovery 
Table 2. Responsiveness Scores of the Modified Observer’s Assess-
ment of Alertness/Sedation Scale
Response Score level
Responds readily to name spoken in normal tone
Lethargic response to name spoken in normal tone
Responds only after name is called loudly or repeatedly
Responds only after mild prodding or shaking
Does not respond to mild prodding or shaking
Does not respond to noxious stimuli
      5 (Alert)
4
3
2
1
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room.
There was no difference in the VAS score among the groups 
at the time when the subjects were in the recovery room and 
during the time until 6 hours and 24 hours after leaving the 
recovery room (Fig. 2). The percentage of patients to whom 
ketorolac was injected for severe pain was 26.6% (8 subjects) 
in the O Group, 20% (6 subjects) in the M group, and 33.3% (10 
subjects) in the MO group (Table 3).
Discussion
In a recent study, five risk factors of the Korean PONV 
model were listed as: female gender, history of PONV or 
kinesia, nonsmoking, surgery longer than one hour, and use of 
opioids combined with IV-PCA. As the number of risk factors 
increased from 0 to 5, the mean expected incidence rate of 
PONV increased from 12.7% to 19.9%, 29.3%, 40.7%, 53.1%, and 
65.4%, respectively [13]. Each type of surgery had a different 
PONV incidence rate: the PONV incidence rate was high in 
gynecologic surgery, laparoscopic surgery, abdominal surgery, 
augmentation mammoplasty, strabismus surgery, ENT surgery, 
Fig. 1. The incidence of PONV at each postoperative time interval 
is shown. Value are numbers (%) of patients. Ondansetron 16 mg is 
added to PCA of group O. Midazolam 5 mg is added to PCA of group 
M. Ondansetron 16 mg and midazolam 5 mg are added to PCA of 
group MO. P < 0.05 is considered statistically significant. *P < 0.05 is 
compared with Group O. PONV:  postoperative nausea and vomiting, 
PCA:  patient controlled analgesia.
Fig. 2. VAS pain scores at each postoperative time interval is shown.   
The VAS pain scores decrease with time in all groups, but there are 
no significant differences among the groups. Value are mean ± SD. 
Ondansetron 16 mg is added to PCA of group O. Midazolam 5 mg 
is added to PCA of group M. Ondansetron 16 mg and midazolam 5 
mg are added to PCA of group MO. VAS:  visual analog scale,  PCA:   
patient controlled analgesia.  
Table 3. Rescue Medications
 Group O 
  (n = 30)
  Group M 
  (n = 30)
 Group MO 
 (n = 30)
Antiemetic agent
Antiemetic agent
  (Above twice)
Ketorolac
Flumazenil
16 (53.3%)
6 (37.5%)
8 (26.6%)
0 (0%)
8 (26.7%)
1 (12.5%)
6 (20%)
0 (0%)
10 (33.3%)
4 (40%)
10 (33.3%)
0 (0%)
Values are numbers (%) of patients. A 16 mg of ondansetron is added 
to the PCA of group O; 5 mg of midazolam is added to the PCA of 
group M; 16 mg of ondansetron and 5 mg of midazolam are added 
to the PCA of group MO. Antiemetic agent: ondansetron, meto-
clopramide and dexamethasone. PCA: patient-controlled analgesia.
Table 4. Degree of Sedation
Group O
(n = 30)
Group M
(n = 30)
Group MO
(n = 30)
Score (PACU)
    5
    4
    3
    2
    1
    0
Score (6 hr)
    5
    4
    3
    2
    1
    0
Score (24 hr)
    5
    4
    3
    2
    1
    0
12 (40%)
18 (60%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
16 (53.3%)
14 (46.7%)
 0 (0%)
 0 (0%)
 0 (0%)
 0 (0%)
  25 (83.3%)
   5 (16.7%)
0 (0%)
  0 (0%)
0 (0%)
0 (0%)
12 (40%)
18 (60%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
 12 (40%)
18 (60%)
 0 (0%)
 0 (0%)
 0 (0%)
 0 (0%)
 21 (70%)
  9 (30%)
 0 (0%)
 0 (0%)
0 (0%)
0 (0%)
17 (56.7%)
13 (43.3%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
  19 (63.3%)
 11 (36.7%)
 0 (0%)
 0 (0%)
 0 (0%)
 0 (0%)
 21 (70%)
  9 (30%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
Values are numbers(%) of patients. A 16 mg of ondansetron is added 
to the PCA of group O; 5 mg of  midazolam is added to the PCA of 
group M; 16 mg of ondansetron and 5 mg of midazolam are added to 
the PCA of group MO. The degree of sedation is scored by modified 
observer’s assessment of alertness/sedation scale. There are no 
significant differences among the groups. 347 www.ekja.org
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surgery of the testis, and surgery of the shoulder [14]. In our 
study, patients who had a past history of smoking, PONV, 
or kinesia were excluded, and those who were to undergo 
a pelviscopic gynecological surgery were included as study 
subjects. The estimated PONV incidence rate in this study from 
the Korean PONV model was 53.1%. The PONV incidence rate 
of the O, M, and MO groups when the patients were in the 
recovery room was 43.3%, 16.7%, and 16.7%, respectively. The 
PONV incidence rate of the O, M, and MO groups from the time 
of the recovery room to 24 hours after leaving the recovery room 
was 63.3%, 46.7%, 33.3%, respectively. The PONV incidence rate 
when the patients were in the recovery room was lower than 
expected in all the groups, but that of the O Group for 24 hours 
after leaving the recovery room was 63.3%, higher than 53.1%, 
which was the incidence rate expected from the Korean PONV 
model. 
IV-PCA, which is used for postoperative pain control, may 
increase the overall satisfaction of the patients by minimizing 
respiratory failure, reducing respiratory system complications, 
and enhancing the analgesic effect [15], but it may also increase 
the frequency and intensity of PONV when combined with the 
opioids [16]. However, PONV occurrence because of the use 
of an opioid combined with IV-PCA can be prevented by the 
use an appropriate antiemetic, and serotonin antagonists that 
selectively antagonize 5-HT3 receptor are often used.
Different from other 5-hydroxytryptamine (5-HT) receptors, 
the 5-HT3 receptor is a ligand-gated cation channel that is 
controlled by the ligand belonging to the nicotine/γ-aminobutyric 
acid (GABA) receptor. The serotonin antagonists that selectively 
antagonize the 5-HT3 receptor do not have a specific reaction 
to other 5-HT receptor subtypes and thus have the advantage 
of having no extrapyramidal side effects with drugs such as 
metoclopramide or droperidol. Among them, ondansetron 
not only treats vomiting due to cancer chemotherapy but also 
effectively treats and prevents PONV, although it has mild side 
effects such as headache, constipation, dizziness, and increased 
values in liver function tests [17]. In a study by Kim et al. [2], 4 
mg of ondansetron preventively injected before the start of IV-
PCA decreased the incidence rate of PONV. Boonmak et al. 
[18] continuously infused morphine mixed with 0.2 mg/ml of 
ondansetron for IV-PCA and reported that the PONV incidence 
rate was effectively reduced. Hwang et al. [19] continuously 
performed IV-PCA combined with 8 mg of ondansetron and 
reported that the incidence rate of postoperative nausea 
decreased. On the contrary, Kil et al. [20] asserted that injection 
of expensive ondansetron is less cost-effective than the injection 
of droperidol. Tramer et al. [21] reported that the preventive 
intravenous injection of 8 mg of ondansetron or oral admini-
stration of 16 mg was effective on postoperative vomiting but 
the effect was not clearly seen for nausea. In our study, the 
PONV incidence rate of the O Group for 24 hours after the 
surgery was 63.3%, higher than 53.1%, which was the incidence 
rate expected based on the Korean PONV model, indicating 
that the use of ondansetron alone is not sufficient to reduce the 
PONV incidence rate. It was also reported that the multimodal 
approach, where various antiemetics are mixed and injected 
or antiemetics are combined with total intravenous anesthesia, 
was more effective in preventing PONV in PONV high-risk 
groups [22,23]. Hence, there has been increasing attention 
to the combined administration of ondansetron with other 
antiemetics for the effective prevention of PONV.
Since the antiemetic effect of midazolam, which is used 
for premedication or as an auxiliary drug for induction, in ex-
pectation of sedation, amnesia, and anxiolytic effect, has been 
established, various studies on it have been reported recently. 
Ha et al. [24] reported that 0.075 mg/kg of midazolam injected 
into patients who had undergone thyroidectomy was as effective 
as 4 mg of ondansetron in preventing PONV without delay 
in the recovery time. Jung and Jeon [8] reported that, among 
patients who had undergone total abdominal hysterectomy, IV-
PCA combined with 0.4 mg of midazolam per 1 mg of morphine 
showed a significantly lower PONV incidence rate than that 
of the IV-PCA with just morphine. The antiemetic mechanism 
of midazolam has not been full elucidated. Its anxiolytic 
effect as well as the intensification of the adenosine effect by 
repressing the adenosine reabsorption in the chemoreceptor 
trigger zone may be related to the reduced PONV incidence rate 
[25,26]. The antiemetic effect may be caused by the reduction 
of 5-HT secretion since midazolam binds the GABA receptor 
[27]. A study reported that preoperative anxiety could affect 
the incidence rate of PONV [28]. Thus, reducing anxiety may 
prevent PONV. In addition, the reason why the measured 
incidence rate of PONV was lower than what was expected in 
the recovery room might be because of the midazolam with its 
antiemetic effect.
In this study, a concern was that the sedative effect of mida-
zolam would affect the recovery from the general anesthesia, 
but there was no difference in the OAA/S scores taken when 
the patients were in the recovery room, during the 6 hours 
after leaving the recovery room, and in the period from 6 to 24 
hours after leaving recovery room (Table 4). Additionally, no 
patients had an OAA/S score of 3 or lower 24 hours after leaving 
the recovery room or had any side effects such as respiratory 
failure. Thus, if a higher dose of midazolam had been infused, 
the antiemetic effect would have been maximized.
The comparison of the VAS scores among the groups showed 
that there were no significant differences when the patients 
were in the recovery room, during the 6 hours after leaving 
the recovery room, and from 6 to 24 hours after. However, the 
ketorolac-demanding rate in the M Group was 20%, which was 348 www.ekja.org
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lower than that of the other groups (Table 3). If midazolam and 
fentanyl are combined for induction, the does can be reduced 
when compared to the single use of an opioid, since they have a 
synergistic effect [29]. Even though the ketorolac and additional 
antiemetic demanding rate was higher in the MO group than 
that of the other groups, the results of the M group indicate 
that the synergistic effect of midazolam and fentanyl may 
have an effect on the fentanyl demand and on the incidence 
rate of PONV. If the number of IV-PCA bolus injections had 
been measured, it could have been determined whether the 
fentanyl demand decreased because of the administration of 
the midazolam, and whether the increased fentanyl demand 
affected the incidence rate of PONV as the number of IV-
PCA bolus injections increased; this is a limitation of this 
study. Additionally, if the effect of the respective antiemetics 
combined with the IV-PCA had been followed up for more than 
one day, a more meaningful result would have been produced. 
Although it is expected that the PONV preventing effect of the 
additional midazolam injection may be reduced over time 
following surgery, a more significant result would have been 
obtained if the study population was larger.
In conclusion, midazolam administration combined with 
IV-PCA was effective in reducing the immediate postoperative 
incidence rate of PONV and the mixed administration of 
ondansetron and midazolam combined with IV-PCA was more 
effective in reducing the incidence rate of PONV.
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